Home >
Access the latest news, business developments, company updates, industry trends, events and more.
Shareholders of Achillion Pharmaceuticals have overwhelmingly approved the company’s takeover by fellow New Haven-born drug maker Alexion Pharmaceuticals for $930 million. Achillion said approximately 99...
Almost every course in the UConn entrepreneurship curriculum has moved away from exam-based assessment and theoretical course content, in favor of building and doing. Furthermore,...
Human somatic cell genome editing is a promising treatment option for cardiovascular disorders, but concerns remain about the safety and efficacy of this therapeutic strategy....
Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a pivotal...
UConn President Thomas Katsouleas set an ambitious goal last February to double research funding at the state’s flagship university over the next decade. A key part...
Achillion Pharmaceuticals has reported top-line data from a dose-finding Phase 2 trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor...
About 50% of human DNA today is made of duplicated sequences that are the remnants of transposition events that took place in our evolutionary history....
Scientists routinely capture images of the brain in action by focusing on single molecules, cells, or circuits. But visualizing how these tiny units interact to...
Cybrexa Therapeutics reports it is expanding the application of its proprietary alphalex™ platform to include toxin conjugates and additional next generation synthetic lethality targets. Two...
A group of researchers from the UConn School of Medicine have received a nearly $3 million grant from the National Institutes of Health to investigate...